CHICAGO / Feb 14, 2024 / Business Wire / GE HealthCare (Nasdaq: GEHC), is announcing today that its Vice President and Chief Financial Officer, Jay Saccaro, will be presenting at the following upcoming investor conferences.
These events can be accessed by visiting GE HealthCare’s Investor Relations website: https://investor.gehealthcare.com/news-events/events on the dates and times listed above.
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 100 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a $19.6 billion business with 51,000 employees working to create a world where healthcare has no limits.
Follow us on LinkedIn, X (formerly Twitter), and Insights for the latest news, or visit our website gehealthcare.com for more information.
| Last Trade: | US$73.79 |
| Daily Change: | 3.92 5.61 |
| Daily Volume: | 3,780,826 |
| Market Cap: | US$33.710B |
May 02, 2025 April 30, 2025 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
